<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010590</url>
  </required_header>
  <id_info>
    <org_study_id>2021P002125</org_study_id>
    <nct_id>NCT05010590</nct_id>
  </id_info>
  <brief_title>Anabolic Therapy in Postmenopausal Osteoporosis</brief_title>
  <official_title>Anabolic Therapy in Postmenopausal Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study we want to learn more about the effect of two different FDA-approved&#xD;
      medications in the treatment of osteoporosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total hip areal bone mineral density</measure>
    <time_frame>Month 0 to 12</time_frame>
    <description>Change in total hip bone density between month 0 and month 12</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Postmenopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Romosozumab and denosumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Romosozumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Romosozumab</intervention_name>
    <description>Monthly romosozumab</description>
    <arm_group_label>Romosozumab</arm_group_label>
    <arm_group_label>Romosozumab and denosumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>Every 6 months denosumab</description>
    <arm_group_label>Romosozumab and denosumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women at high risk of fracture&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy exclusions&#xD;
&#xD;
               1. current use or use in the past 12 months of oral bisphosphonates or denosumab&#xD;
&#xD;
               2. current use or use within the past 3 months of estrogens, selective estrogen&#xD;
                  receptor modulators, or calcitonin.&#xD;
&#xD;
               3. use of oral or parenteral glucocorticoids for more than 14 days within the past 6&#xD;
                  months&#xD;
&#xD;
               4. any current or previous use of romosozumab, strontium, teriparatide,&#xD;
                  abaloparatide, or any parenteral bisphosphonate.&#xD;
&#xD;
        Other exclusions&#xD;
&#xD;
          1. Confirmed serum alkaline greater than 2 times the upper normal limit).&#xD;
&#xD;
          2. Stage 4 or 5 chronic kidney disease (GFR less than 30)&#xD;
&#xD;
          3. Hypercalcemia (Calcium greater than 10.5 mg/dL)&#xD;
&#xD;
          4. Hypocalcemia (Calcium less than 8.8 mg/dL)&#xD;
&#xD;
          5. Elevated blood parathyroid hormone (PTH) (intact PTH greater than 65 pg/ml)&#xD;
&#xD;
          6. Serum 25-hydroxy vitamin D less than 20 ng/ml&#xD;
&#xD;
          7. Hematocrit less than 32%.&#xD;
&#xD;
          8. History of malignancy (except basal cell carcinoma).&#xD;
&#xD;
          9. Significant pulmonary disease&#xD;
&#xD;
         10. History of myocardial infarction or stroke within the preceding year.&#xD;
&#xD;
         11. History of unstable angina or transient ischemic attack in the past year.&#xD;
&#xD;
         12. Current atrial fibrillation.&#xD;
&#xD;
         13. Any health condition that, in the opinion of the study physician, significantly&#xD;
             increases the risk of cardiovascular events.&#xD;
&#xD;
         14. Major psychiatric disease that in the opinion of the investigator would preclude the&#xD;
             subject from providing adequate informed consent or completing the protocol&#xD;
             procedures.&#xD;
&#xD;
         15. Excessive alcohol use or substance abuse that in the opinion of the investigator would&#xD;
             preclude the subject from providing adequate informed consent or completing the&#xD;
             protocol procedures.&#xD;
&#xD;
         16. Uncontrolled eczema&#xD;
&#xD;
         17. Congenital or acquired bone disease other than osteoporosis&#xD;
&#xD;
         18. Known sensitivity to denosumab or any of its excipients.&#xD;
&#xD;
         19. Known sensitivity to romosozumab or any of its excipients.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postmenopausal women</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Leder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mass. General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Savannah Ryan</last_name>
    <phone>6177266129</phone>
    <email>sryan16@mgh.harvard.edu</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Benjamin Leder, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

